CoChat

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Open access
Ridker, Paul M, MacFadyen, Jean G, Thuren, Tom, Everett, Brendan M, Libby, Peter, Glynn, Robert J, Ridker, Paul, Lorenzatti, Alberto, Krum, Henry, Varigos, John, Siostrzonek, Peter, Sinnaeve, Peter, Fonseca, Francisco, Nicolau, Jose, Gotcheva, Nina, Genest, Jacques, Yong, Huo, Urina-Triana, Miguel, Milicic, Davor, Cifkova, Renata, Vettus, Riina, Koenig, Wolfgang, Anker, Stephan D, Manolis, Athanasios J, Wyss, Fernando, Forster, Tamas, Sigurdsson, Axel, Pais, Prem, Fucili, Alessandro, Ogawa, Hisao, Shimokawa, Hiroaki, Veze, Irina, Petrauskiene, Birute, Salvador, Leon, Kastelein, John, Cornel, Jan Hein, Klemsdal, Tor Ole, Medina, Felix, Budaj, Andrzej, Vida-Simiti, Luminita, Kobalava, Zhanna, Otasevic, Petar, Pella, Daniel, Lainscak, Mitja, Seung, Ki-Bae, Commerford, Patrick, Dellborg, Mikael, Donath, Marc, Hwang, Juey-Jen, Kultursay, Hakan, Flather, Marcus, Ballantyne, Christie, Bilazarian, Seth, Chang, William, East, Cara, Everett, Brendan, Forgosh, Les, Glynn, Robert, Harris, Barry, Libby, Peter, Ligueros, Monica, Thuren, Tom, Bohula, Erin, Charmarthi, Bindu, Cheng, Susan, Chou, Sherry, Danik, Jacqueline, McMahon, Graham, Maron, Bradley, Ning, MingMing, Olenchock, Benjamin, Pande, Reena, Perlstein, Todd, Pradhan, Aruna, Rost, Natalia, Singhal, Aneesh, Taqueti, Viviany, Wei, Nancy, Burris, Howard, Cioffi, Angela, Dalseg, Anne Marie, Ghosh, Nilanjan, Gralow, Julie, Mayer, Tina, Rugo, Hope, Fowler, Vance, Limaye, Ajit P, Cosgrove, Sara, Levine, Donald, Lopes, Renato, Scott, John, Thuren, Tom, Ligueros, Monica, Hilkert, Robert, Tamesby, Georgia, Mickel, Carolyn, Manning, Brian, Woelcke, Julian, Tan, Monique, Manfreda, Sheryl, Ponce, Tom, Kam, Jane, Saini, Ravinder, Banker, Kehur, Salko, Thomas, Nandy, Panjat, Tawfik, Ronda, O'Neil, Greg, Manne, Shobha, Jirvankar, Pravin, Lal, Shankar, Nema, Deepak, Jose, Jaison, Collins, Rory, Bailey, Kent, Blumenthal, Roger, Colhoun, Helen, Gersh, Bernard, Glynn, Robert J · 2017 · The Lancet

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Abstract

Background Inflammation in the tumour microenvironment mediated by interleukin 1β is hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did an additional analysis in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), a randomised trial of the role of interleukin-1β inhibition in atherosclerosis, with the aim of establishing whether inhibition of a major product of the Nod-like receptor protein 3 (NLRP3) inflammasome with canakinumab might alter cancer incidence.Methods We did a randomised, double-blind, placebo-controlled trial of canakinumab in 10 061 patients with atherosclerosis who had had a myocardial infarction, were free of previously diagnosed cancer, and had concentrations of high-sensitivity C-reactive protein (hsCRP) of 2 mg/L or greater. To assess dose-response effects, patients were randomly assigned by computer-generated codes to three canakinumab doses (50 mg, 150 mg, and 300 mg, subcutaneously every 3 months) or placebo. Participants were followed up for incident cancer diagnoses, which were adjudicated by an oncology endpoint committee masked to drug or dose allocation. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, NCT01327846. The trial is closed (the last patient visit was in June, 2017).Findings Baseline concentrations of hsCRP (median 6·0 mg/L vs 4·2 mg/L; p<0·0001) and interleukin 6 (3·2 vs 2·6 ng/L; p<0·0001) were significantly higher among participants subsequently diagnosed with lung cancer than among those not diagnosed with cancer. During median follow-up of 3·7 years, compared with placebo, canakinumab was associated with dose-dependent reductions in concentrations of hsCRP of 26-41% and of interleukin 6 of 25-43% (p<0·0001 for all comparisons). Total cancer mortality (n=196) was significantly lower in the pooled canakinumab group than in the placebo group (p=0·0007 for trend across groups), but was significantly lower than placebo only in the 300 mg group individually (hazard ratio [HR] 0·49 [95% CI 0·31-0·75]; p=0·0009). Incident lung cancer (n=129) was significantly less frequent in the 150 mg (HR 0·61 [95% CI 0·39-0·97]; p=0·034) and 300 mg groups (HR 0·33 [95% CI 0·18-0·59]; p<0·0001; p<0·0001 for trend across groups). Lung cancer mortality was significantly less common in the canakinumab 300 mg group than in the placebo group (HR 0·23 [95% CI 0·10-0·54]; p=0·0002) and in the pooled canakinumab population than in the placebo group (p=0·0002 for trend across groups). Fatal infections or sepsis were significantly more common in the canakinumab groups than in the placebo group. All-cause mortality did not differ significantly between the canakinumab and placebo groups (HR 0·94 [95% CI 0·83-1·06]; p=0·31).Interpretation Our hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality. Replication of these data in formal settings of cancer screening and treatment is required.Funding Novartis Pharmaceuticals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)32247-x

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 1,344

Metadata

Authors
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., Siostrzonek, P., Sinnaeve, P., Fonseca, F., Nicolau, J., Gotcheva, N., Genest, J., Yong, H., Urina-Triana, M., Milicic, D., Cifkova, R., Vettus, R., Koenig, W., Anker, S. D., Manolis, A. J., Wyss, F., Forster, T., Sigurdsson, A., Pais, P., Fucili, A., Ogawa, H., Shimokawa, H., Veze, I., Petrauskiene, B., Salvador, L., Kastelein, J., Cornel, J. H., Klemsdal, T. O., Medina, F., Budaj, A., Vida-Simiti, L., Kobalava, Z., Otasevic, P., Pella, D., Lainscak, M., Seung, K.-B., Commerford, P., Dellborg, M., Donath, M., Hwang, J.-J., Kultursay, H., Flather, M., Ballantyne, C., Bilazarian, S., Chang, W., East, C., Everett, B., Forgosh, L., Glynn, R., Harris, B., Libby, P., Ligueros, M., Thuren, T., Bohula, E., Charmarthi, B., Cheng, S., Chou, S., Danik, J., McMahon, G., Maron, B., Ning, M., Olenchock, B., Pande, R., Perlstein, T., Pradhan, A., Rost, N., Singhal, A., Taqueti, V., Wei, N., Burris, H., Cioffi, A., Dalseg, A. M., Ghosh, N., Gralow, J., Mayer, T., Rugo, H., Fowler, V., Limaye, A. P., Cosgrove, S., Levine, D., Lopes, R., Scott, J., Thuren, T., Ligueros, M., Hilkert, R., Tamesby, G., Mickel, C., Manning, B., Woelcke, J., Tan, M., Manfreda, S., Ponce, T., Kam, J., Saini, R., Banker, K., Salko, T., Nandy, P., Tawfik, R., O'Neil, G., Manne, S., Jirvankar, P., Lal, S., Nema, D., Jose, J., Collins, R., Bailey, K., Blumenthal, R., Colhoun, H., Gersh, B., & Glynn, R. J.
Affiliations
  • Brigham and Women's Hospital (US)
  • Novartis (Switzerland) (CH)
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-10
Volume
390
Issue
10105
Pages
1833-1842
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2750254726
Cited by
1,344
References
34
Citations by year
2026: 132 · 2025: 127 · 2024: 164 · 2023: 147 · 2022: 142 · 2021: 140 · 2020: 164 · 2019: 155 · 2018: 142 · 2017: 30
FWCI
54.57
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
Funders
  • Wellcome Trust (206632/Z/17/Z)
  • National Institute of Neurological Disorders and Stroke (K23NS073806)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords
canakinumab, IL-1β inhibition, lung cancer incidence, atherosclerosis, NLRP3 inflammasome, inflammation and cancer, high-sensitivity C-reactive protein, interleukin-6, cancer mortality, myocardial infarction, CANTOS trial, tumor microenvironment, dose-response relationship
MeSH terms
Aged, Anti-Inflammatory Agents, Antibodies, Monoclonal, C-Reactive Protein, Cell Transformation, Neoplastic, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Myocardial Infarction, Neutropenia, Smoking, Thrombocytopenia, Interleukin-6, Incidence, Sepsis, Atherosclerosis, Interleukin-1beta, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)32247-x
The paper
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., Siostrzonek, P., Sinnaeve, P., Fonseca, F., Nicolau, J., Gotcheva, N., Genest, J., Yong, H., Urina-Triana, M., Milicic, D., . . . Glynn, R. J. (2017). Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)32247-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.